StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.88 | $1.73 | -8.08% | 0.1M |
| 05-12 | $1.74 | $1.69 | -2.87% | 0.1M |
| 05-13 | $1.65 | $1.59 | -3.64% | 0.1M |
| 05-14 | $1.61 | $1.79 | +11.18% | 0.2M |
| 05-15 | $1.75 | $1.72 | -1.71% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $14.00K | $81.00K | $71.00K | $55.00K |
Operating Income | $-9.36M | $-36.50M | $-27.55M | $-18.57M |
Net Income | $-8.40M | $-31.93M | $-24.05M | $-8.05M |
EPS (Diluted) | $-0.17 | $-0.67 | $-0.51 | $-0.36 |
Total Assets | $93.54M | $101.93M | $108.13M | $111.83M |
Total Liabilities | $25.92M | $26.52M | $25.94M | $23.60M |
Cash & Equivalents | $4.17M | $3.94M | $4.08M | $5.02M |
Free Cash Flow OCF − CapEx | $-8.78M | $-26.35M | $-19.90M | $-13.31M |
Shares Outstanding | 50.26M | 47.66M | 46.88M | 45.54M |